Cancer Institute– A national cancer institute
designated cancer center

Sandy Srinivas

Back to Profile

Publication Details

  • Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

    Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. J Clin Oncol. 2013; 31 (4): 412-9

    Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort.

    PubMedID: 23169517

Stanford Medicine Resources:

Footer Links: